CHARM 可预测老年人异基因移植后的老年病学并发症与毒性:BMT CTN 1704 研究
研究在 BMT CTN 1704 研究中前瞻性评估复合健康评估风险模型(CHARM)对 1105 例≥60 岁接受异基因造血细胞移植(alloHCT)患者的预后价值。结果显示,CHARM 评分较高与残疾、衰弱、PROMIS 身体功能变差、抑郁、D100 严重器官毒性、D100 认知下降以及急性移植物抗宿主病(GVHD)后死亡率升高独立相关,并可预测无残疾生存和无衰弱生存较差。作者认为移植前 CHARM 是辅助老年患者共同决策的新工具。
要点
- CHARM 评分较高与 D100 残疾、衰弱、PROMIS 身体功能变差独立相关。
- CHARM 评分较高预测无残疾生存(OR 2.03)和无衰弱生存(OR 2.00)较差。
- 作者认为移植前 CHARM 是辅助老年患者共同决策的新工具。
核心结论
- CHARM 是独立的预后评分系统,不仅预测非复发死亡(NRM),也预测 alloHCT 后 1 年内的老年病学并发症和无功能受限生存。
- 作者认为移植前 CHARM 是辅助老年患者共同决策的新工具。
研究设计与样本
- 前瞻性评估复合健康评估风险模型(CHARM)的预后影响,该评分用于预测 1 年非复发死亡(NRM)。
- 纳入骨髓移植临床试验网络研究 1704 中 1105 例年龄≥60 岁的患者。
- 次要终点在 alloHCT 后第 100 天(D100)、D180 和 D365 采用校正预定临床变量的多变量模型评估。
- 试验注册号为 NCT03992352。
主要发现
- 在 alloHCT 存活者中,工具性日常生活活动(IADL)残疾、身体衰弱表型判定的衰弱和患者报告测量信息系统(PROMIS)判定的身体功能受损的患病率在 D100 最高,D180 和 D365 较低。
- CHARM 评分较高与更大残疾独立相关(系数 -0.64;95%CI -0.85 至 -0.43;P<.001)。
- CHARM 评分较高与衰弱增加独立相关(系数 0.19;95%CI 0.081-0.31;P<.001)。
- CHARM 评分较高与 PROMIS 身体功能更差、PROMIS 抑郁更重、D100 严重器官毒性增加、D100 认知下降更多以及急性 GVHD 后死亡率更高相关。
- CHARM 评分较高与 PROMIS 焦虑或急性 GVHD 无显著相关。
关键数值与推荐
- CHARM 评分较高与残疾的系数为 -0.64(95%CI -0.85 至 -0.43;P<.001)。
- CHARM 评分较高与衰弱的系数为 0.19(95%CI 0.081-0.31;P<.001)。
- CHARM 评分较高预测无残疾生存较差的 OR 为 2.03(95%CI 1.66-2.48;P<.001)。
- CHARM 评分较高预测无衰弱生存较差的 OR 为 2.00(95%CI 1.61-2.49)。
临床怎么用
- 作者认为移植前 CHARM 是辅助老年患者共同决策的新工具。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite concerns about the toxicity of allogeneic hematopoietic cell transplantation (alloHCT) in older patients, prospective data characterizing prevalence or risk stratification for geriatric morbidity such as disability or frailty are limited. We prospectively assessed the prognostic impact of the novel composite health assessment risk model (CHARM), a score established to predict 1-year nonrelapse mortality (NRM), among 1105 patients aged ≥60 years enrolled on the Bone Marrow Transplant Clinical Trials Network Study 1704. Secondary end points were assessed post-alloHCT at day 100 (D100), D180, and D365 in multivariable models adjusted with predetermined clinical variables. Among alloHCT survivors, the prevalence of disability by instrumental activities of daily living (IADL), frailty by the Physical Frailty Phenotype, and physical function impairment by Patient Reported Measurement Information System (PROMIS) was highest at D100 and lower on D180 and D365. Higher CHARM scores were independently associated with greater disability (coefficient, -0.64; 95% confidence interval [CI], -0.85 to -0.43; P< .001), increased frailty (coefficient, 0.19; CI, 0.081-0.31; P< .001), worse PROMIS physical function, greater PROMIS depression, increased serious organ toxicity by D100, more cognitive decline at D100, and higher mortality after acute graft-versus-host disease (GVHD) but not significantly associated with PROMIS anxiety or acute GVHD. Higher CHARM scores predicted worse disability-free survival (odds ratio [OR], 2.03; CI, 1.66-2.48; P< .001) and lower frailty-free survival (OR, 2.00; CI, 1.61-2.49). In summary, CHARM is an independent prognostic scoring system not only for NRM but also for geriatric morbidity and functional limitation-free survival through 1 year after alloHCT. Pre-alloHCT CHARM is a novel tool to aid shared decision-making for older patients. This trial was registered at www.clinicaltrials.gov as #NCT03992352.
引用
- Artz AS, Logan B, Saber W, et al. CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study. Blood Adv. 2026. PMID: 41269781. doi:10.1182/bloodadvances.2025018340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。